User: Guest

PEPTIDE THERAPEUTICS

Global Market Trajectory & Analytics

MCP13908

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

9382

Interactions with Platform & by Email *

INTERACTIONS

1313

Unique # Participated *

PARTICIPANTS

281

Responses Validated *

VALIDATIONS

126

* Login to view program details and full enterprise executive list.


  •  DATE

    JULY 2020

  •  TABLES

    309

  •  PAGES

    385

  •  EDITION

    5

  •  PRICE

    USD $5450


COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Peptide Therapeutics estimated at US$27.2 Billion in the year 2020, is projected to reach a revised size of US$47 Billion by 2027, growing at a CAGR of 8.1% over the period 2020-2027.Innovative, one of the segments analyzed in the report, is projected to grow at a 6.6% CAGR to reach US$28 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 10.6% CAGR for the next 7-year period. This segment currently accounts for a 34.5% share of the global Peptide Therapeutics market.
The Peptide Therapeutics market in the U.S. is estimated at US$7.4 Billion in the year 2020. The country currently accounts for a 27.04% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$10.5 Billion in the year 2027 trailing a CAGR of 12.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR while Rest of European market (as defined in the study) will reach US$10.5 Billion by the year 2027.We bring years of research experience to this 5th edition of our report. The 385-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, AbbVie, Inc.; Advanced Accelerator Applications SA; Akashi Therapeutics, Inc.; Amgen, Inc.; Anthera Pharmaceuticals, Inc.; AstraZeneca PLC; Bachem AG; Bristol-Myers Squibb Company; Cardiorentis AG; Corden Pharma International GmbH; Debiopharm Group; Derma Sciences, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Hanmi Pharmaceutical Co., Ltd.; Insmed, Inc.; Ipsen Group; Johnson & Johnson; Lonza Group AG; Mallinckrodt PLC; Merck & Co., Inc.; MolMed S.p.A.; Novartis AG; Novo Nordisk A/S; Nymox Pharmaceutical Corporation; PAR Pharmaceutical Companies, Inc.; PeptiDream Inc.; Pfizer, Inc.; PolyPeptide Group; Radius Health, Inc.; Repligen Corporation; Sanofi SA; SciClone Pharmaceuticals Holding Limited.; Shire PLC; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; The Medicines Company; X-GEN Pharmaceuticals, Inc.; Zealand Pharma A/S; Zydus Cadila
» Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, Other Applications) » Technology (Liquid Phase, Solid Phase, Hybrid Phase) » Type (Innovative, Generic)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com